AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
It definitely looks like a negative result overall with revenues falling 19% short of analyst estimates at US$6.5m. Statutory losses were US$0.17 per share, 31% bigger than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. Check out our latest analysis for AbCellera Biologics Taking into account the latest results, the current consensus from AbCellera Biologics' ten analysts is for revenues of US$45.0m in 2025. This would reflect a sizeable 37% increase on its revenue over the past 12 months. Per-share losses are predicted to creep up to US$0.65. Before this latest report, the consensus had been expecting revenues of US$50.5m and US$0.65 per share in losses. So there's been quite a ch
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera to Present at Upcoming Investor Conferences in December and January [Yahoo! Finance]Yahoo! Finance
- AbCellera to Present at Upcoming Investor Conferences in December and JanuaryBusiness Wire
- AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 [Yahoo! Finance]Yahoo! Finance
- AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024Business Wire
- AbCellera Biologics Inc. (NASDAQ: ABCL) had its "hold" rating re-affirmed by analysts at Benchmark Co..MarketBeat
ABCL
Earnings
- 11/4/24 - Miss
ABCL
Sec Filings
- 11/14/24 - Form SC
- 11/4/24 - Form 10-Q
- 11/4/24 - Form 8-K
- ABCL's page on the SEC website